Mesenchymal Stem Cells Ameliorate Hyperglycemia in Type I Diabetic Developing Male Rats

Area of Science:

• Endocrinology
• Regenerative Medicine
• Cell Biology

Background:

• Diabetes Mellitus (DM) poses a significant global health challenge.
• Stem cell therapy, particularly with Mesenchymal Stem Cells (MSCs), is an emerging therapeutic strategy for DM.
• Streptozotocin (STZ) induced diabetes in rats is a widely used model to study DM pathogenesis and treatment.

Purpose of the Study:

• To investigate the antidiabetic effects of MSCs in a rat model of STZ-induced DM.
• To evaluate the impact of early-stage MSC administration on glycemic control and pancreatic function.
• To assess the histological and ultrastructural changes in pancreatic islet cells following MSC therapy.

Main Methods:

• Twenty-four male rats were divided into control, diabetic, and two diabetic groups receiving MSCs at different time points post-STZ induction.
• Biochemical parameters including glucose, insulin, C-peptide, HbA1c, MDA, TAS, and TOS were measured.
• Insulin resistance (HOMA-IR), beta cell function (HOMA-β), and oxidative stress index (OSI) were calculated.
• Histopathological and ultrastructural analyses of pancreatic tissues were performed.

Main Results:

• STZ-induced diabetic rats exhibited significant impairments in glycemic control, insulin regulation, and oxidative balance.
• Histopathological analysis revealed destructive effects on pancreatic islet cells in diabetic rats.
• Early-stage MSC therapy significantly reversed biochemical alterations and restored pancreatic islet cell structure and function.
• MSC treatment led to improved glycemic homeostasis and beta cell restoration.

Conclusions:

• Mesenchymal stem cell therapy demonstrates significant potential in treating STZ-induced diabetes mellitus.
• Early intervention with MSCs is crucial for effective beta cell restoration and glycemic control.
• MSC therapy offers a promising regenerative approach for managing diabetes and its complications.